Food, Drugs, Healthcare, Life Sciences

Researchers at UNSW are transforming wine and coffee byproducts into sustainable, high-performance battery materials, addressing environmental challenges in lithium-ion technology. This innovation supports circular economies, green energy transitions, and demands robust intellectual property strategies for commercial success.

Until recently, Massachusetts was the only state that did not maintain a licensing regime for nonresident pharmacies...

As reported in last month's blog here, Ordinance 309 on Denver's November 2024 ballot could have prohibited the construction, maintenance, or use of meat production facilities within Denver city limits.

Starting on 1 January 2025, the parallel import of medicines into Ukraine will come into force, allowing dealers that are authorised by manufacturers of medicinal products to import medicines in parallel...

The list of entities subject to monitoring and certain reporting obligations in Austria extends beyond the provisions of the MDR and the IVDR. It includes persons and entities that use medical devices...

Marshall Gerstein Partner Kate Neville recently joined The Biotech Startups Podcast host Jon Chee for a four-episode conversation that dived into numerous areas of Kate's work...

Queensland's healthcare system can rise to meet the demands of the future.

On December 3, 2024, United States District Court Judge Amos Mazzant issued a nationwide order enjoining the Corporate Transparency Act (CTA), a law which required nearly all types of corporate entities to submit beneficial owner information to the Treasury Department.

Until recently, Massachusetts was the only state that did not maintain a licensing regime for nonresident pharmacies...

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

Health Canada specifically contemplates certain proteins as SEBs in its Guidance, although Health Canada has not limited SEBs to only particular classes of drugs.

On May 23, 2012, the Federal Court held that Merck Frosst Canada Ltd. ("Merck") is liable to Apotex Inc. ("Apotex") for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations"), but exercised its discretion to reduce the amount of compensation payable based on a defence of ex turpi causa.